Literature DB >> 1765775

Human parvovirus B19 specific IgG, IgA, and IgM antibodies and DNA in serum specimens from persons with erythema infectiosum.

D D Erdman1, M J Usher, C Tsou, E O Caul, G W Gary, S Kajigaya, N S Young, L J Anderson.   

Abstract

To determine the diagnostic use of different markers of acute parvovirus B19 infection, serum specimens obtained from 128 persons with erythema infectiosum were tested for specific immunoglobulin G (IgG), IgA, and IgM antibodies by capture enzyme immunoassay (EIA) using Chinese hamster ovary (CHO) cell-expressed B19 antigen, and tested for circulating B19 DNA by polymerase chain reaction (PCR). A significant rise in specific IgG and IgA antibodies was detected in 87% and 77%, respectively, of persons from whom acute- and convalescent-phase serum specimens were available. Specific IgA antibodies were detected in single serum specimens from 90% of cases and were present in 22 (18%) of 120 persons from a control group without a history of recent exposure to B19. Specific IgM antibodies were detected in 97% of cases and one person (1%) from the control group. B19 DNA was detected in 94% of cases and was absent in 20 persons from the control group positive for both IgG and IgA antibodies. Serum specimens obtained between 4 and 6 months after onset of illness from six additional persons were also tested. All had specific IgG antibodies, four (67%) had IgA, five (83%) had IgM, and none had detectable B19 DNA. Our data indicate that 1) specific IgA antibodies are too persistent to be a useful indicator of recent B19 infection; 2) specific IgM antibodies are the most sensitive indicator of acute B19 infection in immunologically normal persons but can persist up to 6 months; and 3) B19 DNA can often be detected up to 2 months after onset of illness even in immunologically normal hosts and might be a useful adjunct test for diagnosis of acute B19 infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1765775     DOI: 10.1002/jmv.1890350207

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  19 in total

Review 1.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

2.  Parvovirus infection mimicking systemic lupus erythematosus.

Authors:  Mohan Cooray; Joshua J Manolakos; Douglas S Wright; Shariq Haider; Ameen Patel
Journal:  CMAJ       Date:  2013-08-26       Impact factor: 8.262

Review 3.  Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements.

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Gabriele Calizzani; Fabio Candura; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-04       Impact factor: 3.443

Review 4.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

5.  Seroprevalence of human parvovirus B19 in healthy blood donors.

Authors:  Satish Kumar; R M Gupta; Sourav Sen; R S Sarkar; J Philip; Atul Kotwal; S H Sumathi
Journal:  Med J Armed Forces India       Date:  2013-02-23

6.  Acute-phase-specific heptapeptide epitope for diagnosis of parvovirus B19 infection.

Authors:  L Kaikkonen; H Lankinen; I Harjunpää; K Hokynar; M Söderlund-Venermo; C Oker-Blom; L Hedman; K Hedman
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

Review 7.  Parvovirus B19 infection.

Authors:  J R Kerr
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

8.  Use of recombinant human parvovirus B19 antigens in serological assays.

Authors:  H A Cubie; E E Leslie; S Smith; H J O'Neill; H Hart; B J Cohen; J M Inglis
Journal:  J Clin Pathol       Date:  1993-09       Impact factor: 3.411

Review 9.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

10.  Parvovirus B19 infection in HIV-1 infected patients with anemia.

Authors:  K Gyllensten; A Sönnerborg; C Jorup-Rönström; M Halvarsson; Z Yun
Journal:  Infection       Date:  1994 Sep-Oct       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.